Sign In
Buy ASMB
$24.57
+0.0800 (+0.327%)
At Close: Jun 03, 2026
Assembly Biosciences Announces Upcoming Investor Conference Presentations
04:05pm, Thursday, 28'th May 2026
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
07:05am, Friday, 22'nd May 2026
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver di
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
07:00am, Friday, 22'nd May 2026
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
07:06am, Thursday, 14'th May 2026
Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing pr
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:20pm, Wednesday, 13'th May 2026
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
02:00am, Wednesday, 13'th May 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
08:00am, Monday, 11'th May 2026
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
06:16pm, Thursday, 07'th May 2026
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $1.17 per share a year ago.
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
04:00pm, Thursday, 07'th May 2026
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule ent
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentatio
Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75
01:12am, Saturday, 21'st Mar 2026
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the stock, MarketBeat Ratings reports.
Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development
01:55pm, Friday, 20'th Mar 2026
Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HD
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
06:20pm, Thursday, 19'th Mar 2026
Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to a loss of $1.57 per share a year ag
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
04:05pm, Thursday, 19'th Mar 2026
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development p
